ADMA Biologics Inc (NASDAQ:ADMA) – Oppenheimer increased their FY2018 EPS estimates for shares of ADMA Biologics in a note issued to investors on Wednesday, October 3rd. Oppenheimer analyst L. Gershell now expects that the biotechnology company will earn ($1.40) per share for the year, up from their prior estimate of ($1.43). Oppenheimer currently has a “Buy” rating and a $13.00 target price on the stock. Oppenheimer also issued estimates for ADMA Biologics’ Q4 2018 earnings at ($0.34) EPS, Q1 2019 earnings at ($0.25) EPS, Q4 2019 earnings at ($0.19) EPS, FY2019 earnings at ($0.90) EPS, FY2020 earnings at ($0.32) EPS, FY2021 earnings at $0.17 EPS and FY2022 earnings at $0.91 EPS.
A number of other brokerages have also weighed in on ADMA. Maxim Group restated a “buy” rating and issued a $12.00 target price on shares of ADMA Biologics in a research report on Wednesday, September 5th. BidaskClub upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. Chardan Capital began coverage on shares of ADMA Biologics in a research report on Monday, July 30th. They issued a “buy” rating and a $10.00 target price on the stock. ValuEngine upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Thursday, July 26th. Finally, LADENBURG THALM/SH SH cut their target price on shares of ADMA Biologics to $7.50 and set a “buy” rating on the stock in a research report on Wednesday, June 13th. Seven analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $9.50.
ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Friday, August 10th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%. The company had revenue of $4.66 million during the quarter, compared to analyst estimates of $5.35 million.
Several large investors have recently modified their holdings of ADMA. AMP Capital Investors Ltd acquired a new position in shares of ADMA Biologics during the second quarter worth $109,000. Element Capital Management LLC acquired a new position in shares of ADMA Biologics during the first quarter worth $118,000. Renaissance Technologies LLC acquired a new position in shares of ADMA Biologics during the second quarter worth $132,000. Schwab Charles Investment Management Inc. acquired a new position in shares of ADMA Biologics during the second quarter worth $160,000. Finally, Spark Investment Management LLC lifted its holdings in shares of ADMA Biologics by 68.7% during the second quarter. Spark Investment Management LLC now owns 37,460 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 15,260 shares during the period. Institutional investors own 55.08% of the company’s stock.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Featured Article: What is the Dividend Aristocrat Index?
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.